Response on bioequivalence for biotherapeutic drugs

We have had the opportunity to read your letter related to our review article: "Biotherapeutic drugs: use of botulinum toxins in the era of biosimilars". We would like to express our agreement with your comments on the relevance of the subject in our environment, as well as with your refle...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta Neurológica Colombiana 2024-01, Vol.40 (1)
Hauptverfasser: Martínez, José David, Henao, Paula Cavanzo, Sobrino, Fidel, Ramírez, Sergio, Arango, Gabriel, Zuluaga, Andrés, Rendón, Laura
Format: Artikel
Sprache:spa
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page
container_title Acta Neurológica Colombiana
container_volume 40
creator Martínez, José David
Henao, Paula Cavanzo
Sobrino, Fidel
Ramírez, Sergio
Arango, Gabriel
Zuluaga, Andrés
Rendón, Laura
description We have had the opportunity to read your letter related to our review article: "Biotherapeutic drugs: use of botulinum toxins in the era of biosimilars". We would like to express our agreement with your comments on the relevance of the subject in our environment, as well as with your reflections on the interchangeability of drugs and the need to clarify the concepts on the subject very well.In particular, you refer to the confusion that can be generated by the phrase in our conclusion: "biological drugs are not interchangeable with each other, even if they demonstrate bioequivalence". With interest we read how many of our colleagues were confused with the last part of the sentence because it is contradictory, since as you classically mention "bioequivalence studies are carried out to demonstrate that the generic drug is equivalent and interchangeable with the original drug".
doi_str_mv 10.22379/anc.v40i1.1219
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_3077967282</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3077967282</sourcerecordid><originalsourceid>FETCH-proquest_journals_30779672823</originalsourceid><addsrcrecordid>eNqNikELgjAYQEcUJOW566Cz9u1TnDtH0Tm6i9lnTWTTzfn7K-gHdHrw3mNsJyBFzKQ61KZJ5xy0SAUKtWAR5ohJDohLFoFASEqZl2sWe98BAColiqKMWHYlP1jjiVvD79rSGPRc92Qa4q11XzW9yNUDhUk3_OHC02_Zqq17T_GPG7Y_n27HSzI4OwbyU9XZ4MwnVRlIqQqJJWb_XW8YijyB</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3077967282</pqid></control><display><type>article</type><title>Response on bioequivalence for biotherapeutic drugs</title><source>DOAJ Directory of Open Access Journals</source><source>Alma/SFX Local Collection</source><creator>Martínez, José David ; Henao, Paula Cavanzo ; Sobrino, Fidel ; Ramírez, Sergio ; Arango, Gabriel ; Zuluaga, Andrés ; Rendón, Laura</creator><creatorcontrib>Martínez, José David ; Henao, Paula Cavanzo ; Sobrino, Fidel ; Ramírez, Sergio ; Arango, Gabriel ; Zuluaga, Andrés ; Rendón, Laura</creatorcontrib><description>We have had the opportunity to read your letter related to our review article: "Biotherapeutic drugs: use of botulinum toxins in the era of biosimilars". We would like to express our agreement with your comments on the relevance of the subject in our environment, as well as with your reflections on the interchangeability of drugs and the need to clarify the concepts on the subject very well.In particular, you refer to the confusion that can be generated by the phrase in our conclusion: "biological drugs are not interchangeable with each other, even if they demonstrate bioequivalence". With interest we read how many of our colleagues were confused with the last part of the sentence because it is contradictory, since as you classically mention "bioequivalence studies are carried out to demonstrate that the generic drug is equivalent and interchangeable with the original drug".</description><identifier>ISSN: 0120-8748</identifier><identifier>EISSN: 2422-4022</identifier><identifier>DOI: 10.22379/anc.v40i1.1219</identifier><language>spa</language><publisher>Bogota: Asociación Colombiana de Neurología</publisher><subject>Bioequivalence ; Biological products ; Drugs</subject><ispartof>Acta Neurológica Colombiana, 2024-01, Vol.40 (1)</ispartof><rights>2024. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Martínez, José David</creatorcontrib><creatorcontrib>Henao, Paula Cavanzo</creatorcontrib><creatorcontrib>Sobrino, Fidel</creatorcontrib><creatorcontrib>Ramírez, Sergio</creatorcontrib><creatorcontrib>Arango, Gabriel</creatorcontrib><creatorcontrib>Zuluaga, Andrés</creatorcontrib><creatorcontrib>Rendón, Laura</creatorcontrib><title>Response on bioequivalence for biotherapeutic drugs</title><title>Acta Neurológica Colombiana</title><description>We have had the opportunity to read your letter related to our review article: "Biotherapeutic drugs: use of botulinum toxins in the era of biosimilars". We would like to express our agreement with your comments on the relevance of the subject in our environment, as well as with your reflections on the interchangeability of drugs and the need to clarify the concepts on the subject very well.In particular, you refer to the confusion that can be generated by the phrase in our conclusion: "biological drugs are not interchangeable with each other, even if they demonstrate bioequivalence". With interest we read how many of our colleagues were confused with the last part of the sentence because it is contradictory, since as you classically mention "bioequivalence studies are carried out to demonstrate that the generic drug is equivalent and interchangeable with the original drug".</description><subject>Bioequivalence</subject><subject>Biological products</subject><subject>Drugs</subject><issn>0120-8748</issn><issn>2422-4022</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqNikELgjAYQEcUJOW566Cz9u1TnDtH0Tm6i9lnTWTTzfn7K-gHdHrw3mNsJyBFzKQ61KZJ5xy0SAUKtWAR5ohJDohLFoFASEqZl2sWe98BAColiqKMWHYlP1jjiVvD79rSGPRc92Qa4q11XzW9yNUDhUk3_OHC02_Zqq17T_GPG7Y_n27HSzI4OwbyU9XZ4MwnVRlIqQqJJWb_XW8YijyB</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Martínez, José David</creator><creator>Henao, Paula Cavanzo</creator><creator>Sobrino, Fidel</creator><creator>Ramírez, Sergio</creator><creator>Arango, Gabriel</creator><creator>Zuluaga, Andrés</creator><creator>Rendón, Laura</creator><general>Asociación Colombiana de Neurología</general><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20240101</creationdate><title>Response on bioequivalence for biotherapeutic drugs</title><author>Martínez, José David ; Henao, Paula Cavanzo ; Sobrino, Fidel ; Ramírez, Sergio ; Arango, Gabriel ; Zuluaga, Andrés ; Rendón, Laura</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_30779672823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2024</creationdate><topic>Bioequivalence</topic><topic>Biological products</topic><topic>Drugs</topic><toplevel>online_resources</toplevel><creatorcontrib>Martínez, José David</creatorcontrib><creatorcontrib>Henao, Paula Cavanzo</creatorcontrib><creatorcontrib>Sobrino, Fidel</creatorcontrib><creatorcontrib>Ramírez, Sergio</creatorcontrib><creatorcontrib>Arango, Gabriel</creatorcontrib><creatorcontrib>Zuluaga, Andrés</creatorcontrib><creatorcontrib>Rendón, Laura</creatorcontrib><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Acta Neurológica Colombiana</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martínez, José David</au><au>Henao, Paula Cavanzo</au><au>Sobrino, Fidel</au><au>Ramírez, Sergio</au><au>Arango, Gabriel</au><au>Zuluaga, Andrés</au><au>Rendón, Laura</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response on bioequivalence for biotherapeutic drugs</atitle><jtitle>Acta Neurológica Colombiana</jtitle><date>2024-01-01</date><risdate>2024</risdate><volume>40</volume><issue>1</issue><issn>0120-8748</issn><eissn>2422-4022</eissn><abstract>We have had the opportunity to read your letter related to our review article: "Biotherapeutic drugs: use of botulinum toxins in the era of biosimilars". We would like to express our agreement with your comments on the relevance of the subject in our environment, as well as with your reflections on the interchangeability of drugs and the need to clarify the concepts on the subject very well.In particular, you refer to the confusion that can be generated by the phrase in our conclusion: "biological drugs are not interchangeable with each other, even if they demonstrate bioequivalence". With interest we read how many of our colleagues were confused with the last part of the sentence because it is contradictory, since as you classically mention "bioequivalence studies are carried out to demonstrate that the generic drug is equivalent and interchangeable with the original drug".</abstract><cop>Bogota</cop><pub>Asociación Colombiana de Neurología</pub><doi>10.22379/anc.v40i1.1219</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0120-8748
ispartof Acta Neurológica Colombiana, 2024-01, Vol.40 (1)
issn 0120-8748
2422-4022
language spa
recordid cdi_proquest_journals_3077967282
source DOAJ Directory of Open Access Journals; Alma/SFX Local Collection
subjects Bioequivalence
Biological products
Drugs
title Response on bioequivalence for biotherapeutic drugs
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T07%3A16%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response%20on%20bioequivalence%20for%20biotherapeutic%20drugs&rft.jtitle=Acta%20Neurol%C3%B3gica%20Colombiana&rft.au=Mart%C3%ADnez,%20Jos%C3%A9%20David&rft.date=2024-01-01&rft.volume=40&rft.issue=1&rft.issn=0120-8748&rft.eissn=2422-4022&rft_id=info:doi/10.22379/anc.v40i1.1219&rft_dat=%3Cproquest%3E3077967282%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3077967282&rft_id=info:pmid/&rfr_iscdi=true